evoke semaglutide trial and evoke+: design of two large‐scale, double‐blind, placebo‐controlled, phase 3 studies evaluating the neuroprotective effects of in early Alzheimer's disease - Atri - 2022 - Alzheimer's & Dementia Trial design of evoke/evoke+. *Participants

The study conducted by Pi-Sunyer et al

doi:10.1039/d2fo02017c Grone M, Sansone R, Hoffken P, et al

Never stop injecting abruptly

CAM2043 Raynauds phenomenon CAM2043 is a long-acting subcutaneous treprostinil depot being developed for the treatment of Raynauds phenomenon secondary to systemic sclerosis

This review highlights tirzepatide, a novel dual agonist of GLP-1 and GIP receptors, which has demonstrated significant improvements in glycemic control, weight loss, and potential cardiovascular and renal benefits, marking it as a promising advancement in T2D treatment

Missing a single dose will not reverse your weight loss